<p>[新加坡] 医疗服务提供商杰俐（Thomson Medical）在截至 2025 年 12 月 31 日的上半年报告净亏损 1020 万新元，较上年同期的 1290 万新元净亏损有所收窄。</p>
<p>该公司在周三（2 月 11 日）的一份交易所公告中表示，尽管杰俐在其市场上持续投资于专业服务、临床人才和数字化举措，但由于净融资成本降低和运营表现稳定，才出现了这样的结果。</p>
<p>上半年收入同比增长 7%，达到 2.131 亿新元，去年同期为 1.991 亿新元。</p>
<p>收入增长主要得益于新加坡的强劲贡献、企业折扣减少后改善的定价纪律，以及 2024 年 11 月开始运营的马来西亚肿瘤中心的新收入。</p>
<p>越南的收入因患者数量增加而上升。然而，杰俐表示，这一增长部分被越南盾的不利外汇影响所抵消。</p>
<p>杰俐集团首席执行官邓美文（Dr Melvin Heng）表示：“收入增长仍然是我们战略是否有效的最明确指标，这些结果表明我们的运营业务对过去几年的投资反应良好。”</p>
<p>他补充说，增长来自于集团加大投入的领域：新加坡更深入的多学科护理、马来西亚的专业服务（如肿瘤科）以及越南不断增加的患者数量。</p>
<p>净融资成本减少 460 万新元，降至 2420 万新元。这主要是由于利率降低和贷款及借款的偿还，部分被短期存款的利息收入下降所抵消。</p>
<p>由于与马来西亚肿瘤中心相关的药品成本上升，以及新加坡和越南药品和耗材成本增加，2026 财年上半年库存和消耗品使用增加至 5560 万新元。</p>
<p>由于在数字化转型举措和市场活动上的支出增加，其他运营费用在上半年略微上升至 4690 万新元。</p>
<p>上半年员工成本较去年同期增长 5.3%，主要归因于新加坡和越南员工人数的增加。</p>
<p>展望未来，集团表示将继续优先考虑收入增长，同时加强在医院和专业平台的执行力。</p>
<p>杰俐计划改善其诊所和医院设施网络，推出第二个生育中心，并加强与保险公司的合作，以改善对专业护理的获取。</p>
<p>在马来西亚，杰俐医院（Thomson Hospital Kota Damansara）扩展了其专业领域，包括肿瘤中心，而杰俐生育中心已重新品牌为生殖医学的领先中心。</p>
<p>此外，与支付方和企业的合作，以及计划在柔佛州建设的杰俐医院（Thomson Hospital Iskandariah），将支持医疗旅游和该地区的老龄化人口。</p>
<p>在越南，FV 医院将在 2027 年底前扩展 H 翼，拓宽肿瘤、诊断和先进外科服务，同时继续支持社会健康保险和分期付款计划。</p>
<p>这些举措将使杰俐能够捕捉到不断增长的国内需求和区域医疗旅游，得益于政府对私营医疗的支持，集团表示。</p>
<p>杰俐的股票在周三收盘时上涨 1.6%，或 0.001 新元，报 0.062 新元，此前发布了其业绩。</p>

杰俐

<p>杰俐报告称，2026 财年上半年净亏损收窄至 1020 万新元，较 1290 万新元有所下降，主要受益于融资成本降低和运营稳定。收入增长 7%，达到 2.131 亿新元，归因于新加坡和马来西亚的增长，尽管越南受到外汇影响。该集团计划提升服务并扩展设施，包括新建生育中心和合作伙伴关系，以促进医疗旅游。公告发布后，股价上涨 1.6%，至 0.062 新元</p>

<p>[SINGAPORE] Healthcare provider Thomson Medical has posted a net loss of S$10.2 million for the first half ended Dec 31, 2025, narrowing from a net loss of S$12.9 million in the previous corresponding period.</p>
<div class="lb-trans"><p>[新加坡] 医疗服务提供商杰俐（Thomson Medical）在截至 2025 年 12 月 31 日的上半年报告净亏损 1020 万新元，较上年同期的 1290 万新元净亏损有所收窄。</p>
</div><p>This came amid lower net finance costs and steady operating performance, even as Thomson Medical sustained investments in specialist services, clinical talent and digital initiatives across its markets, said the group in a bourse filing on Wednesday (Feb 11).</p>
<div class="lb-trans"><p>该公司在周三（2 月 11 日）的一份交易所公告中表示，尽管杰俐在其市场上持续投资于专业服务、临床人才和数字化举措，但由于净融资成本降低和运营表现稳定，才出现了这样的结果。</p>
</div><p>Revenue for the half-year period rose 7 per cent to S$213.1 million, from S$199.1 million in the year-ago period.</p>
<div class="lb-trans"><p>上半年收入同比增长 7%，达到 2.131 亿新元，去年同期为 1.991 亿新元。</p>
</div><p>Growth in the top line was due to stronger contributions from Singapore, improved pricing discipline following a reduction in corporate discounts, as well as new takings from the oncology centre in Malaysia which started operating in November 2024.</p>
<div class="lb-trans"><p>收入增长主要得益于新加坡的强劲贡献、企业折扣减少后改善的定价纪律，以及 2024 年 11 月开始运营的马来西亚肿瘤中心的新收入。</p>
</div><p>Revenue in Vietnam rose from higher patient volumes. However, the increase was partially offset by an unfavourable foreign exchange impact from the Vietnamese dong, said Thomson Medical.</p>
<div class="lb-trans"><p>越南的收入因患者数量增加而上升。然而，杰俐表示，这一增长部分被越南盾的不利外汇影响所抵消。</p>
</div><p>“Revenue growth remains the clearest indicator of whether our strategy is working, and these results show that our operating businesses are responding well to the investments we have made over the past few years,” said Dr Melvin Heng, group chief executive officer of Thomson Medical Group.</p>
<div class="lb-trans"><p>杰俐集团首席执行官邓美文（Dr Melvin Heng）表示：“收入增长仍然是我们战略是否有效的最明确指标，这些结果表明我们的运营业务对过去几年的投资反应良好。”</p>
</div><p>He added that growth is coming from the areas that the group has been doubling down on: deeper multidisciplinary care in Singapore, specialist services such as oncology in Malaysia and rising patient volumes in Vietnam.</p>
<div class="lb-trans"><p>他补充说，增长来自于集团加大投入的领域：新加坡更深入的多学科护理、马来西亚的专业服务（如肿瘤科）以及越南不断增加的患者数量。</p>
</div><p>Net finance costs decreased S$4.6 million to S$24.2 million. This is mainly due to lower interest rates and repayment of loans and borrowings, which is partially offset by the lower interest income from short-term deposits.</p>
<div class="lb-trans"><p>净融资成本减少 460 万新元，降至 2420 万新元。这主要是由于利率降低和贷款及借款的偿还，部分被短期存款的利息收入下降所抵消。</p>
</div><p>Inventories and consumables used were higher at S$55.6 million during H1 FY2026 due to higher drug costs associated with the oncology centre in Malaysia, as well as increased drugs and consumables costs in Singapore and Vietnam.</p>
<div class="lb-trans"><p>由于与马来西亚肿瘤中心相关的药品成本上升，以及新加坡和越南药品和耗材成本增加，2026 财年上半年库存和消耗品使用增加至 5560 万新元。</p>
</div><p>Other operating expenses rose slightly to S$46.9 million in the half-year period, due to higher expenditure on digital transformation initiatives and marketing activities.</p>
<div class="lb-trans"><p>由于在数字化转型举措和市场活动上的支出增加，其他运营费用在上半年略微上升至 4690 万新元。</p>
</div><p>Staff costs in H1 rose 5.3 per cent compared with the same period last year and was attributed to higher headcount in Singapore and Vietnam.</p>
<div class="lb-trans"><p>上半年员工成本较去年同期增长 5.3%，主要归因于新加坡和越南员工人数的增加。</p>
</div><p>Looking ahead, the group said it will continue prioritising revenue growth while sharpening execution across its hospitals and specialist platforms.</p>
<div class="lb-trans"><p>展望未来，集团表示将继续优先考虑收入增长，同时加强在医院和专业平台的执行力。</p>
</div><p>Thomson Medical plans to improve its network of clinics and hospital facilities, launch a second fertility centre and strengthen insurance partnerships to improve access to specialised care.</p>
<div class="lb-trans"><p>杰俐计划改善其诊所和医院设施网络，推出第二个生育中心，并加强与保险公司的合作，以改善对专业护理的获取。</p>
</div><p>In Malaysia, Thomson Hospital Kota Damansara has expanded its specialties, including the oncology centre, while Thomson Fertility has been rebranded as a leading centre in reproductive medicine.</p>
<div class="lb-trans"><p>在马来西亚，杰俐医院（Thomson Hospital Kota Damansara）扩展了其专业领域，包括肿瘤中心，而杰俐生育中心已重新品牌为生殖医学的领先中心。</p>
</div><p>Additionally, partnerships with payors and corporates, as well as the planned Thomson Hospital Iskandariah in Johor, will supporting medical tourism and the region’s ageing population.</p>
<div class="lb-trans"><p>此外，与支付方和企业的合作，以及计划在柔佛州建设的杰俐医院（Thomson Hospital Iskandariah），将支持医疗旅游和该地区的老龄化人口。</p>
</div><p>In Vietnam, FV Hospital will expand with the H-wing by end-2027, broadening oncology, diagnostics, and advanced surgical services, while continuing to support social health insurance and instalment-based programmes.</p>
<div class="lb-trans"><p>在越南，FV 医院将在 2027 年底前扩展 H 翼，拓宽肿瘤、诊断和先进外科服务，同时继续支持社会健康保险和分期付款计划。</p>
</div><p>These initiatives will allow Thomson Medical to capture rising domestic demand and regional medical tourism, underpinned by government support for private healthcare, said the group.</p>
<div class="lb-trans"><p>这些举措将使杰俐能够捕捉到不断增长的国内需求和区域医疗旅游，得益于政府对私营医疗的支持，集团表示。</p>
</div><p>Shares of Thomson Medical ended Wednesday 1.6 per cent or S$0.001 higher at S$0.062, before the release of its results.</p>
<div class="lb-trans"><p>杰俐的股票在周三收盘时上涨 1.6%，或 0.001 新元，报 0.062 新元，此前发布了其业绩。</p>
</div>

杰俐因财务成本降低和运营稳定，将上半年净亏损缩小至 1020 万新加坡元